Last update 01 Nov 2024

BRK x EGFR x Eph x RET x SRC family x VEGFR x Tie-2

Basic Info

Related Targets
BRKEGFREph[+4]

Related

1
Drugs associated with BRK x EGFR x Eph x RET x SRC family x VEGFR x Tie-2
Vandetanib
Target
BRK x EGFR x Eph x RET x SRC family x Tie-2 x VEGFR
Mechanism
BRK inhibitors [+6]
Active Org.
Genzyme Corp.Genzyme Corp. [+6]
Originator Org.
AstraZeneca Pharmaceuticals Co. Ltd.AstraZeneca Pharmaceuticals Co. Ltd.
Active Indication
RET Mutation-Positive Medullary Thyroid Cancer [+4]
Inactive Indication
Advanced Bile Duct Carcinoma [+56]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date06 Apr 2011
131
Clinical Trials associated with BRK x EGFR x Eph x RET x SRC family x VEGFR x Tie-2
NCT06482086 / RecruitingPhase 2IIT
Precision Medicine Applied to Locally Advanced Thyroid Cancer Using Tumor-derived Organoids and In-vitro Sensitivity Testing: a Phase 2a, Single-center, Open-label, and Non-comparative Study
100 Clinical Results associated with BRK x EGFR x Eph x RET x SRC family x VEGFR x Tie-2
Login to view more data
100 Translational Medicine associated with BRK x EGFR x Eph x RET x SRC family x VEGFR x Tie-2
Login to view more data
0 Patents (Medical) associated with BRK x EGFR x Eph x RET x SRC family x VEGFR x Tie-2
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free